CNETS participates in and supports QEII fall publication on Ga68/NETSPOT accessibility in Atlantic Canada. The QEII Times and the Chronicle Herald published a two-page spread on Saturday, October 16, [...]
Les Cancers Endocriniens, published in Le Médecin du Québec, October 2021 Dre. Cynthia Landry is a primary care physician in Châteauguay, Quebec, working as an emergency physician [...]
Our amazing Hamilton/Halton/Niagara NET Support Group Leader, Vannesa Mann, shares her inspirational story! Zoomer | September 10th, 2021 For people with neuroendocrine tumours, early diagnosis and timely [...]
Volunteers create one-of-a-kind handmade Pewter Zebra Keyfobs/Pendants to help raise awareness & funds for CNETS Al Gillis is a neuroendocrine cancer patient and member of the Toronto Patient and [...]
CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]
As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]
The Globe and Mail: How a better image can save a life Sharon Needham, with oncologist Dr. Daniel Rayson, and radiologist Dr. Steven Burrell, at [...]
Disclaimer: CNETS is a patient organization, and we are unable to provide medical advice. Any information or guidance contained herein should not replace personalized medical advice. Our objective is [...]
CNETS is happy to announce that BC Cancer will now reimburse LUTATHERA for the approved indication. The BC Cancer Benefit Drug List, Published March 2021, Tumour Site: Gastrointestinal Peptide [...]
INSPIRATIONAL NEUROENDOCRINE CANCER PATIENT STORY Long-time CNETS fundraisers Bryde Fresque and Natalie Mezey, share a message of hope! As outlined in this Ottawa Hospital Foundation report, Bryde Fresque [...]